Estimates Revisions Compass Therapeutics, Inc.
Stocks
CMPX
US20454B1044
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
04:00:00 02/10/2026 HKT
|
Pre-market 21:02:19 | |||
| 0.9011 USD | -13.36% |
|
0.9420 | +4.54% |
| 09-24 | Compass Therapeutics Shares Drop After Downgrade From Wedbush | MT |
| 09-23 | Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- CMPX Stock
- Consensus Compass Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
